Clinical Trials
131 trialsNCT04985643 2026-05-22
LEADER
Takeda
Active not recruiting
NCT05742217 2026-05-14
MUST
Pfizer
Active not recruiting
NCT05160584 2026-05-08
MoMMent
Janssen Pharmaceutica N.V., Belgium
Recruiting
NCT06285318 2026-05-08
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06472778 2026-05-08
A Real-world Study in Participants With Smoldering Multiple Myeloma
Janssen-Cilag Ltd.
Completed
NCT07391761 2026-05-06
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Pfizer
Not yet recruiting
NCT07559799 2026-04-30
MARINA
iOMEDICO AG
Not yet recruiting
NCT01081028 2026-04-13
Connect® MM- The Multiple Myeloma Disease Registry
Celgene
Terminated
NCT07354555 2026-03-20
MMExFFPE
BIWAKO
Not yet recruiting
NCT07482761 2026-03-19
MM-t4-14-FFPE
BIWAKO
Not yet recruiting
NCT05332054 2026-03-12
LTFS
Caribou Biosciences, Inc.
Enrolling by invitation
NCT04328662 2026-03-04
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
Completed
NCT05974150 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Carevive Systems, Inc.
Recruiting
NCT05879757 2026-02-18
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Takeda
Recruiting
NCT03308474 2026-01-27
MYRIAM
iOMEDICO AG
Recruiting
NCT06357754 2026-01-22
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Bristol-Myers Squibb
Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT05954780 2026-01-14
SEATTLE
iOMEDICO AG
Active not recruiting
NCT05013190 2026-01-08
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
Takeda
Active not recruiting
NCT01838512 2025-12-02
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Bristol-Myers Squibb
Active not recruiting
NCT03106324 2025-11-24
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Active not recruiting
NCT06581848 2025-11-24
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
Pfizer
Active not recruiting
NCT06479954 2025-10-02
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Pfizer
Active not recruiting
NCT05673083 2025-09-04
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
All4Cure
Active not recruiting
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT04458831 2025-06-27
IONA-MM
Sanofi
Active not recruiting
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT07028970 2025-06-19
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Nanjing IASO Biotechnology Co., Ltd.
Recruiting
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT05673967 2025-04-25
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Completed
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT04035226 2025-03-30
LocoMMotion
Janssen-Cilag Ltd.
Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT05735704 2025-03-26
SANGUINE
JaxBio Ltd
Unknown
NCT02761187 2025-02-24
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
Terminated
NCT06825845 2025-02-13
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
CARsgen Therapeutics Co., Ltd.
Not yet recruiting
NCT03180853 2025-02-03
Multiple Myeloma Patient Registry
Janssen Scientific Affairs, LLC
Terminated
NCT03061305 2025-01-31
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Strata Oncology
Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06698887 2024-12-13
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Bristol-Myers Squibb
Recruiting
NCT06539169 2024-11-14
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
Recruiting
NCT05932290 2024-10-29
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT06659770 2024-10-26
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics Co., Ltd.
Not yet recruiting
NCT06323447 2024-10-09
PC002
Leuko Labs, Inc.
Not yet recruiting
NCT05284591 2024-10-01
MYLENE
iOMEDICO AG
Completed
NCT06160167 2024-08-23
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
Bristol-Myers Squibb
Completed
NCT04545333 2024-08-01
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Terminated
NCT04840680 2024-07-24
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
Takeda
Completed
NCT04659798 2024-07-08
DOrianT
Takeda
Completed
NCT03777410 2024-07-03
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Travera Inc
Terminated